Skip to Main Content

Paper Details

Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs.
ACS Pharmacol Transl Sci
1
2023
1-thioxo-2,4-dihydrothieno[2,3-][1,2,4]triazolo[4, 5-thio-1-methyl-4-nitroimidazolyl, 9-fluorophenyl, Anticancer, C, HeLa, L363, PBD, Plk1, Plk1-addicted cancers, Plk2, Plk3 PBDs, Polo-Box Domain, Polo-like Kinase 1, Polo-like kinase 1, cancer, cancers, human, phenyl, polo-box domain, thiol, thiophene, triazoloquinazolinone
Author NameAffiliation
Anton SimeonovDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Beverly A MockCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Frank J GonzalezCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Kenneth A JacobsonNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
  • 1 - 4

Datasets

Release 1.2